The effect of omega-3 polyunsaturated fatty acid supplementation on vascular structure, function, and inflammation in type 1 diabetes: a double-blind, randomised, placebo-controlled trial

L.L. O’Mahoney1, A.M. Alobaid2, R.A. Ajjan3, K.M. Birch4, N.M. Orsi5, G. Mappa5, M. Holmes2, P. Ho2, A. Stavropoulos-Kalinoglou1, O.J. Price1 and M.D. Campbell2

1Carnegie School of Sport, Leeds Beckett University, Leeds, UK,  
2School of Food Science and Nutrition, University of Leeds, Leeds, UK,  
3School of Medicine, University of Leeds, Leeds, UK,  
4School of Biomedical Sciences, University of Leeds, Leeds, UK and  
5Leeds Institute of Cancer & Pathology, St James’s University Hospital, Leeds, UK

Raised inflammation and impaired endothelial function are common in patients with type 1 diabetes (T1D)(1-2). Although increased omega-3 polyunsaturated fatty acid (n-3 PUFA) intake can improve risk factors for macrovascular complications in adults with type 2 diabetes(3), such evidence is limited in T1D. Here, we report findings from a trial examining the effect of 6-month n-3 PUFA supplementation on vascular structure, function, and inflammation in adults with T1D.

For this double-blind, randomised, placebo-controlled trial, individuals with T1D (n = 20; males:16; 34 ± 14 years; BMI: 26.6 ± 5.2 kg/m²; glycated haemoglobin (HbA1c): 58 ± 13 mmol/mol-1 [7.5 ± 3.3%]), were randomly allocated in a 1:1 ratio to receive either 3.3 g/day of encapsulated n-3 PUFA or placebo (PLA) consisting of an encapsulated dose of 3.0 g/day corn oil for 6-months. Fatty acids were measured in erythrocyte membranes by gas chromatography with n-3 PUFA index (O3I) calculated as eicosapentaenoic acid plus docosahexaenoic acid. Carotid artery intima-media thickness (CIMT), flow mediated dilation of the brachial artery (FMD), and biomarkers of vascular inflammation were assessed at baseline and following 6-months supplementation. A paired-samples t test was used to compare intragroup mean differences and an independent samples t test was used for comparisons between n-3 PUFA and PLA at baseline; statistical significance was set at p ≤ 0.05. Data are presented as mean ± SD.

O3I levels were comparable at baseline, increasing significantly under n-3 PUFA, but not PLA, (mean difference: 3.37 ± 1.52% vs. 0.36 ± 0.69%; p < 0.001). All outcome variables were similar between conditions at baseline (p > 0.05). After 6-months n-3 PUFA supplementation, CIMT remained unchanged (0.61 ± 0.12 mm vs. 0.60 ± 0.10 mm; p = 0.200), as did FMD (7.11 ± 1.31% vs. 6.90 ± 1.43%; p = 0.541). Similar findings were observed in the PLA group; CIMT (0.64 ± 0.09 mm vs. 0.64 ± 0.09 mm; p = 0.726) and FMD (7.66 ± 1.95% vs. 7.78 ± 2.58%; p = 0.656). Vascular cell adhesion molecule-1 (p = 0.825), intercellular adhesion molecule-1 (p = 0.65), vascular endothelial growth factor (p = 0.332), E-selectin (p = 0.420), P-selectin (p = 0.390), pentraxin-3 (p = 0.902), and tumor necrosis factor alpha (p = 0.993) remained unchanged in the n-3 PUFA group. Comparable findings were observed in the PLA group (p > 0.05). Overall, no safety issues arose during administration of n-3 PUFA or PLA.

Despite significant increases in erythrocyte n-3 PUFA concentration, a daily high-dose-bolus of n-3 PUFA for 6-months had no effect on vascular structure, function, or inflammation in adults with T1D. These findings do not support the use of n-3 PUFA supplementation in the management of T1D and its associated macrovascular complications.